Oligodendroglioma

P1, N=12, Recruiting, University of Florida | Active, not recruiting --> Recruiting

Gliomas are associated with abnormal CO2- and O2-reactivity measured with MRI. These dynamic parameters may provide new insights into the vascular pathophysiology in gliomas.

P=N/A, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026

P1/2, N=7, Terminated, Dawonmedax Co., Ltd. | N=39 --> 7 | Trial completion date: Dec 2024 --> Jun 2024 | Recruiting --> Terminated; The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial with a revised protocol.

P2, N=60, Recruiting, Rigel Pharmaceuticals | Not yet recruiting --> Recruiting

CSF is a reliable reservoir for ctDNA analyses in patients with gliomas. ctDNA is detectable in plasma although at a lower rate. Larger, prospective studies should be conducted to refine the potential role of liquid biopsy in this disease.

LGG individuals in the low-risk category posses a higher likelihood of being sensitive to Carmustine and Vincristine, as indicated by the drug sensitivity analysis. The qRT-PCR experiment and immunohistochemistry images confirmed that the expression of FPR1, PTAFR, SLC11A1 and ICAM1 are higher in low-grade oligodendroglioma. The NETRGs signature and nomogram can accurately and conveniently predict the LGG patients' prognosis, which can facilitate individualized treatment and the improvement of prognosis.

P1, N=13, Completed, Pediatric Brain Tumor Consortium | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Dec 2024

P1, N=24, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Sep 2025

The efficacy of abemaciclib in recurrent grade 3 oligodendroglioma was inadequate to warrant further evaluation as monotherapy in unselected patients. However, given the objective responses and durable disease control observed in a subset of patients, further studies are warranted to identify subgroups that may benefit.

P=N/A, N=225, Recruiting, Oslo University Hospital | Trial completion date: Dec 2041 --> Dec 2043 | Trial primary completion date: Dec 2025 --> Dec 2027

Integrating perfusion MRI with genetic analysis offers a promising approach to improving the diagnostic and therapeutic landscape for brain tumors, indicating a substantial step toward personalized neuro-oncology. These findings support further validation in larger, multi-institutional studies to solidify their role in clinical practice.

P1, N=102, Recruiting, Chimerix | Trial completion date: Feb 2025 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Dec 2025

In this large cohort of IDHm glioma patients, ivosidenib was well tolerated. Our results support the use of IDHi therapy in patients with grade 2 or 3 astrocytoma or oligodendroglioma and highlight limited effectiveness in patients with enhancing disease.

P4, N=120, Recruiting, Leiden University Medical Center | Trial completion date: Jan 2028 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Jul 2026

P1, N=35, Recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2028 --> Feb 2030 | Trial primary completion date: Aug 2025 --> Apr 2027

To our knowledge, this is the first retrospective study and in silico analysis demonstrating the relevance and correlation of MUC1 and MUC4 in adult gliomas. These findings elucidate the molecular mechanisms underlying adult-type diffuse glioma progression and highlight MUC1 and MUC4 as potential prognostic markers and therapeutic targets for glioma management.

P1, N=12, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting

Inhibiting cathepsin X similarly changed cell morphology and enhanced oligodendrocyte differentiation. These findings suggest that cathepsin X modulates γ-enolase activity and thereby influences oligodendrocyte differentiation and thus neuronal function.

P2, N=36, Recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

Our case suggests that vorasidenib may impart therapeutic benefits in this setting. This case illustrates the need for further investigation into these less commonly addressed scenarios and treatment strategies that extend beyond current guidelines.

The accuracy in diagnosing IDH-mutant astrocytoma, oligodendroglioma, and IDH-wild-type glioblastoma was 0.66, surpassing the human pathologist average of 0.62 (0.54-0.67). In conclusion, GLISP is a two-stage AI framework for histology-based prediction of genetic events in adult gliomas, which is helpful in providing essential information for WHO 2021 molecular diagnoses.

P3, N=540, Active, not recruiting, Eastern Cooperative Oncology Group | Trial primary completion date: Dec 2024 --> Apr 2025

P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2029 --> Mar 2031 | Trial primary completion date: Mar 2029 --> Mar 2031

P1/2, N=231, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2029 --> Jan 2028 | Trial primary completion date: Feb 2029 --> Oct 2027

The results indicated that GPNMB is specifically expressed in all SEGAs, distinguishing it from other morphologically similar tumours. The findings demonstrate specific GPNMB expression in SEGA, underscoring its promise as a diagnostic biomarker.

The cortical high-flow sign on ASL, which is more commonly found in ODG IDHm-codel than in diffuse glioma with IDH-wildtype or astrocytoma, is associated with the histological cortical vascular density in patients with ODG IDHm-codel.

Our findings suggest that NCOA4 could be a potential prognostic marker and therapeutic target in LGG.

P=N/A, N=300, Recruiting, Pediatric Brain Tumor Consortium | Active, not recruiting --> Recruiting

P2, N=44, Not yet recruiting, University Health Network, Toronto

In the IDH-mutant subgroup, it tended to co-occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. These correlations may further refine prognostic predictions.

The calibration curve showed that the established nomogram could well predict the survival based on these covariates. The AA-G3 with IDH-1 wildtype, MGMT unmethylation or 1p/19q non-codeletion patients was resistant to radiotherapy and chemotherapy, has a poor prognosis and needs a more active treatment.

No abstract available

P1, N=60, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=2, Terminated, Wake Forest University Health Sciences | N=36 --> 2 | Suspended --> Terminated; Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study

In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.

Both lack the defining 1p/19q co-deletion or copy-neutral heterozygosity of an oligodendroglioma and oligosarcoma. The findings in this case report both contribute to the apparent heterogeneity of the novel MC oligosarcoma and describe a second reported mesenchymal transformation of an IDH-mutant astrocytoma.

Primary MMRD is more common than previously reported in gliomas in children, adolescents, and young adults, is enriched in specific molecular subgroups, and is associated with poor outcomes. Accurate detection, genetic testing, early diagnosis through surveillance, and implementation of immunotherapy might improve survival for these patients.

TERT mutation was present in the oligodendroglioma component, whereas it was absent in the astrocytoma component. Although rare, gliomas harboring both oligodendroglioma and astrocytoma components in a single tumor exist and show genetically distinct areas.

Tumors in both groups of rats showed a moderate/high expression of the astrocyte marker, GFAP, and the oligodendrocyte marker, OLIG-2, and a low expression of the proliferation marker, Ki-67. However, tumors of the ENU + LY341495 group showed a reduced density of Iba-1+ cells, suggesting a lower extent of neuroinflammation in the tumor microenvironment. These findings strengthen the hypothesis that mGlu3 receptors are candidate drug targets for the treatment of malignant gliomas.

P1, N=10, Completed, Blueprint Medicines Corporation | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> May 2024

In summary, we report the occurrence of PDGFRA hotspot mutation in a neonatal high-grade glioma without distinct features of MGNT, demonstrating that this genetic alteration is not specific to MGNT. We recommend caution in classifying a tumor as MGNT solely by the presence of PDGFRA alteration.